Keywords: ارزیابی جهانی محقق; acne vulgaris; adult acne; scar; post-inflammatory hyperpigmentation; AAD; American Academy of Dermatology; A/BPO; adapalene/benzoyl peroxide; EDF; European Dermatology Forum; FASET; Facial Acne Severity Evaluation Tool; FDA; Food and Drug Administration;
مقالات ISI ارزیابی جهانی محقق (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ارزیابی جهانی محقق; AE; adverse event; CFB; change from baseline; CNT; Coxib and tNSAID Trialists'; CrI; credible interval; CSR; clinical study reports; DIC; deviance information criterion; IGA; investigator global assessment; ITT; intention-to-treat; NMA; network meta-ana
Keywords: ارزیابی جهانی محقق; atopic dermatitis; atopic eczema; flares; long-term control; outcome measures; randomized controlled trials; systematic review; AD; atopic dermatitis; GREAT; Global Resource of Eczema Trials; HOME; Harmonizing Outcome Measures for Eczema; IGA; Investigato
Keywords: ارزیابی جهانی محقق; biomarker; cathelicidin; doxycycline; kallikrein; matrix metalloproteinase; papulopustular; rosacea; serine protease; AE; adverse event; BCA; bicinchoninic acid assay; CAMP; cathelicidin antimicrobial peptide; cDNA; complementary DNA; GAPDH; glyceraldehyd
Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry
Keywords: ارزیابی جهانی محقق; biologic therapy; effectiveness; psoriasis; real-world; registry; safety; systemic therapy; BSA; body surface area; BMI; body mass index; DLQI; Dermatology Life Quality Index; EQ-5D; Euro-QoL-5 Dimensional; EQ-5D-3L; Euro-QoL-5 Dimensional-3 Level; IGA; I
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial
Keywords: ارزیابی جهانی محقق; atopic dermatitis; fezakinumab; IL-22; placebo-controlled trial; moderate-to-severe AD; AD; atopic dermatitis; BSA; body surface area; BMI; body mass index; EASI; Eczema Area and Severity Index; IGA; Investigator Global Assessment; ITT; intention to treat
Olumacostat glasaretil, a novel topical sebum inhibitor, in the treatment of acne vulgaris: A phase IIa, multicenter, randomized, vehicle-controlled study
Keywords: ارزیابی جهانی محقق; acetyl-coenzyme A carboxylase inhibitor; acne vulgaris; inflammatory lesions; investigator global assessment; local skin reactions; noninflammatory lesions; olumacostat glasaretil; AE; adverse event; CoA; coenzyme A; CI; confidence interval; IGA; investig
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-
Keywords: ارزیابی جهانی محقق; adalimumab; efficacy; guselkumab; hand and foot psoriasis; nail psoriasis; psoriasis; safety; scalp psoriasis; VOYAGE 1; VOYAGE 2; AE; adverse event; DLQI; Dermatology Life Quality Index; f-PGA; Fingernail Physician Global Assessment; HRQoL; health-relate
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, p
Keywords: ارزیابی جهانی محقق; adalimumab; efficacy; guselkumab; interleukin-23; psoriasis; safety; switching; VOYAGE 1; VOYAGE 2; AE; adverse event; DLQI; Dermatology Life Quality Index; IGA; Investigator Global Assessment; IL; interleukin; ISR; injection site reaction; MACE; major ad
Original articleTreatment of recalcitrant granuloma annulare (GA) with adalimumab: A single-center, observational study
Keywords: ارزیابی جهانی محقق; adalimumab; etanercept; granuloma annulare; infliximab; Investigator Global Assessment; treatment; tumor necrosis factor-α inhibitor; BSA; body surface area; GA; granuloma annulare; IGA; Investigator Global Assessment; IL; interleukin; TNF; tumor necrosi
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
Keywords: ارزیابی جهانی محقق; clear or almost clear skin; clinical trial; head to head; plaque psoriasis; secukinumab; superiority; ustekinumab; 90% or more improvement in baseline Psoriasis Area and Severity Index; AE; adverse event; DLQI; Dermatology Life Quality Index; HRQoL; healt
Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)
Keywords: ارزیابی جهانی محقق; clinical trial; dosing; immunogenicity; noninferiority; psoriasis; retreatment as needed; secukinumab; AE; adverse event; DLQI; Dermatology Life Quality Index; IGA; investigator global assessment; PASI; Psoriasis Area and Severity Index; PASI 75; 75% or m